Next year, data from the National Eye Institute Lucentis-Avastin Trial ( http://clinicaltrials.gov/ct2/show/NCT00593450 ), should increase Avastin's 65% share of US procedures for wet AMD.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.